|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 2a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Bronchial Allergen Challenge Study to Assess the Safety, Tolerability, and Efficacy of Inhaled AIR645 in Subjects With Mild Allergic Asthma
To assess the efficacy of inhaled AIR645 in the suppression of the Asthmatic Responses in subjects with mild asthma inhaling an allergen.
A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma
This is a phase one study to evaluate the safety, tolerability, and bioavailability of nebulized AIR645.
100 Clinical Results associated with Altair Therapeutics, Inc.
0 Patents (Medical) associated with Altair Therapeutics, Inc.
100 Deals associated with Altair Therapeutics, Inc.
100 Translational Medicine associated with Altair Therapeutics, Inc.